BalanitisMANAGEMENT

GENITOURINARY AND REPRODUCTIVE PRESENTATIONS · 12 SECTIONS

⚲

565 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Acute Kidney Injury (ATN)Acute Kidney Injury (Post-renal)Acute Kidney Injury (Pre-renal)Amniotic Fluid Embolism Balanitis Bladder Rupture Breast Abscess Cystitis Dialysis access complications Ectopic pregnancy Epididymitis Glomerulonephritis Hematuria (gross)Hydrocele Interstitial Cystitis Mastitis Mittelschmerz Nephrolithiasis Nephrotic Syndrome Flare Nutcracker Syndrome Orchitis Ovarian Cyst Rupture Ovarian hyperstimulation syndrome Ovarian torsion Paraphimosis Pelvic Congestion Syndrome Pelvic Inflammatory Disease (PID)Peritoneal dialysis peritonitis Phimosis Priapism Prostatitis Pyelonephritis Renal laceration Renal transplant complications and rejection Ruptured ovarian cyst Testicular torsion Torsion of Appendix Testis Tubo-ovarian abscess Ureteral Rupture Urethritis Urinary Retention Urinary tract infection (uncomplicated)Urolithiasis (renal colic)Vaginal bleeding (non-pregnant)Vaginitis (Bacterial)Vaginitis (Candidal)Varicocele Vulvovaginal Hematoma

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp45

Immediate threats and escalation triggers

›Cannot-miss emergencies

›Fournier's gangrene

›Rapidly spreading erythema with crepitus, necrosis, or skin discolouration beyond glans

›Systemic toxicity: fever, tachycardia, hypotension

›Immediate surgical consultation and IV antibiotics

›Paraphimosis

›Foreskin retracted and trapped proximal to glans with venous engorgement

›Urologic emergency requiring immediate manual reduction

›If reduction fails, emergency dorsal slit or circumcision by urology

›Penile carcinoma with obstruction

›Painless mass, ulcer, or fungating lesion

›Urinary retention secondary to meatal involvement

›Urgent urology referral and biopsy

›Systemic infection criteria

›Cellulitis extending to shaft or scrotum

›IV antibiotics required

›Surgical consultation for abscess or necrotizing features

›Sepsis screening

›Fever with tachycardia and organ dysfunction

›Lactate >= 2 mmol/l as perfusion marker

›Urinary retention

›Meatal stenosis or severe phimosis as cause

›Urologic emergency with catheter or suprapubic drainage

Monitoring and stabilisation targets

›Vital sign targets in complicated cases

›Temperature trending toward normothermia with treatment

›Heart rate < 100 beats/min after fluid resuscitation

02History/hx51

Presenting symptoms

›Core symptom characterisation

›Erythema of glans penis

›Duration and onset: acute vs. chronic or recurrent

›First episode vs. prior episodes with treatments tried

›Pruritus, burning, or pain

›Severity and functional impact

›Dysuria or difficulty voiding

›Discharge character

›White cottage-cheese consistency (candida)

›Purulent or foul-smelling (bacterial)

›Fishy odour (Gardnerella-associated)

›Foreskin and voiding symptoms

›Difficulty retracting foreskin (phimosis)

›Foreskin trapped behind glans and unable to reduce (paraphimosis)

›Meatal narrowing or weak urinary stream

Exposures and triggers

›Recent exposures

›New sexual contact or partner

›STI risk factors: unprotected sex, multiple partners

›Partner symptoms: vaginal candidiasis, bacterial vaginosis, STI

›New soaps, lubricants, condoms, or detergents (irritant dermatitis)

›Recent antibiotic use (promotes candidal overgrowth)

›Hygiene context

›Overwashing with soap or harsh cleansers

›Poor hygiene with smegma accumulation

›Inability to retract foreskin for cleaning

03Physical Exam/exam47

Vital signs and general assessment

›Systemic stability

›Temperature: fever suggests superimposed cellulitis or Fournier's gangrene

›Heart rate and blood pressure: tachycardia and hypotension suggest sepsis

›Respiratory rate: elevated in systemic sepsis

›General appearance

›Degree of distress

›Evidence of systemic illness: diaphoresis, pallor, toxicity

Genital examination

›Glans penis

›Erythema: distribution, intensity, borders

›Diffuse erythema with satellite lesions (candida)

›Well-demarcated shiny red-orange plaque (Zoon balanitis)

›Velvety red plaque without scale (erythroplasia of Queyrat — cannot miss)

›Oedema, erosions, or fissures

›Discharge: colour, consistency, odour

›Ulceration or mass

›Painful vesicles/ulcers (herpes simplex)

›Painless chancre (primary syphilis)

›Painless lump, ulcer, or fungating mass (squamous cell carcinoma)

›Prepuce (foreskin)

›Retractability: phimosis severity grading

›White sclerotic thickening (lichen sclerosus / balanitis xerotica obliterans)

›Fissuring or scarring from chronic inflammation

›Paraphimosis assessment: foreskin trapped and oedematous proximal to glans

›Coronal sulcus and urethral meatus

›Smegma accumulation in coronal sulcus

›Meatal discharge, stenosis, or erythema

04Differential Diagnosis/ddx50

Life-threatening diagnoses

›Surgical emergencies

›Fournier's gangrene (necrotising fasciitis of perineum)

›ICD-10 N49.3

›Crepitus, rapid spread, necrosis, systemic toxicity

›Paraphimosis

›ICD-10 N47.2

›Foreskin entrapped proximal to glans with progressive ischaemia

›Penile squamous cell carcinoma

›ICD-10 C60.9

›Painless mass or ulcer; chronic balanitis is an independent risk factor

Infectious causes

›Candidal balanitis

›ICD-10 B37.42

›Most common infectious cause; accounts for majority of STD clinic cases

›Satellite lesions, cottage-cheese discharge, erythema with glazed appearance

›Bacterial balanitis

›Staphylococcus aureus, Streptococcus pyogenes

›Gardnerella vaginalis: fishy odour, associated with partner BV

›Anaerobic organisms: polymicrobial in smegma environment

›Sexually transmitted infections

›Herpes simplex virus: grouped vesicles or ulcers, painful

›Primary syphilis: painless chancre, ICD-10 A51.0

›Gonorrhoea or chlamydia with urethritis

Non-infectious and dermatological causes

›Irritant and contact dermatitis

›ICD-10 L24.9

›Soaps, lubricants, condom latex exposure

05Laboratory Tests/lt35

Point-of-care and first-line tests

›KOH preparation

›Rapid bedside test for candidal hyphae or pseudohyphae

›Sensitivity moderate; negative does not exclude candida

›Performed on scraping from glans or discharge

›Glucose and HbA1c

›Mandatory in recurrent or refractory balanitis

›Screen for undiagnosed diabetes mellitus

›Poorly controlled HbA1c: OR ~19 for candidal balanitis

›Urinalysis

›Glucosuria suggesting uncontrolled diabetes

›Pyuria if urinary tract infection co-exists

Microbiological tests

›Fungal culture

›Swab for fungal culture if KOH inconclusive

›Direct impression on CHROMagar Candida medium superior to swab for yeast recovery

›Indicated when first-line antifungal therapy fails

›Bacterial culture

›Swab of purulent discharge for sensitivity

›Indicated for cellulitis, purulent drainage, or treatment failure

›Gardnerella balanitis: clue cells on wet mount from discharge

›STI screening

›GC and chlamydia NAAT: if STI risk factors or urethral discharge

›RPR or VDRL: syphilis serology if ulcers or chancre

›HIV testing: if risk factors or immunocompromised presentation

›HSV PCR: if vesicular or ulcerative lesions

Advanced and biopsy-directed tests

›Punch biopsy

06Diagnostic Tests/dt54

Scoring Systems

›Clinical classification system for balanitis

›Infectious aetiology (~54% of cases)

›Candida (most common), bacterial, rarely viral

›Non-infectious aetiology (~41% of cases)

›Irritant dermatitis, psoriasis, lichen sclerosus, Zoon balanitis, fixed drug eruption

›Premalignant or malignant (<5%)

›Erythroplasia of Queyrat, invasive SCC

›Severity stratification

›Uncomplicated

›Localised glans erythema without systemic features

›No phimosis, paraphimosis, urinary retention, or spreading cellulitis

›Complicated

›Phimosis, cellulitis extending beyond glans, urinary retention, systemic toxicity

›Surgical emergency

›Fournier's gangrene, irreducible paraphimosis, suspected malignancy with obstruction

›Dermoscopy scoring for differential diagnosis

›Erythroplasia of Queyrat: glomerular vessels (sensitivity and specificity superior to clinical exam)

›Zoon balanitis: orange structureless areas with curved vessels

›Candidal balanitis: cottage-cheese structured white material

›Dermoscopy accuracy study (Errichetti et al., JEADV 2019) supports this classification

MRI

›Penile MRI indications

›Suspected deep tissue invasion in penile cancer staging

›T2 staging of penile squamous cell carcinoma

›Corpus cavernosum invasion assessment

›Fournier's gangrene extent mapping

›Delineate fascial plane involvement when CT equivocal

07Disposition/dispo30

Discharge criteria

›Uncomplicated balanitis discharge

›No systemic toxicity or fever

›No spreading cellulitis beyond glans

›No urinary retention

›No paraphimosis

›Able to tolerate oral or topical therapy

›Clear discharge instructions and return precautions provided

›Follow-up planning

›Primary care or urology in 1 to 2 weeks if not improving

›Earlier if worsening or no response to initial therapy

›Dermatology referral for chronic or refractory cases

›Endocrinology or primary care for new or poorly controlled diabetes

Admission criteria

›Indications for hospital admission

›Systemic toxicity with fever, tachycardia, or hypotension

›Spreading cellulitis to shaft, scrotum, or perineum

›Fournier's gangrene: immediate surgical admission

›Irreducible paraphimosis requiring procedural or surgical management

›Urinary retention requiring catheterisation or suprapubic drainage

›Immunocompromised host with complicated presentation

Specialist consultation triggers

›Urology indications

›Paraphimosis or significant phimosis

›Suspected penile malignancy

›Urethral stenosis causing retention

›Recurrent balanitis refractory to medical therapy (circumcision discussion)

›Dermatology indications

08Treatment/t81

Initial management and hygiene

›Universal initial measures

›Gentle retraction of foreskin with warm water cleansing; no soap

›Pat area dry after cleaning; keep glans dry

›Avoid all irritants: scented soaps, lubricants, harsh detergents

›Saline soaks for inflamed or oedematous glans

Candidal balanitis (first-line treatment)

›Topical antifungal therapy

›Clotrimazole 1% cream topically twice daily for 7 to 14 days

›First-line therapy; evidence level Class I recommendation

›Apply to glans and inner prepuce

›Miconazole 2% cream topically twice daily for 7 to 14 days

›Equivalent efficacy to clotrimazole

›Oral antifungal for recurrent or refractory candida

›Fluconazole 150 mg orally as single dose

›For recurrent or refractory cases

›Repeat dose at 72 hours if not resolving

›Contraindication: avoid empiric antifungals without considering non-infectious aetiology in chronic cases

Bacterial balanitis treatment

›Topical antibiotic for localised infection

›Mupirocin 2% ointment topically twice to three times daily for 5 to 7 days

›Fusidic acid cream topically twice daily for 7 days

›Oral antibiotics for cellulitis or spreading infection

›Cephalexin 500 mg orally four times daily for 5 to 7 days

›Streptococcal and staphylococcal coverage

›Amoxicillin-clavulanate 875/125 mg orally twice daily for 5 to 7 days

›Broader coverage including anaerobes

›Gardnerella-associated balanitis

›Metronidazole 400 to 500 mg orally twice daily for 7 days

›Concurrent partner treatment for bacterial vaginosis

›IV antibiotics for cellulitis with systemic toxicity

›Cefazolin 1 to 2 g IV every 8 hours as initial therapy

›Piperacillin-tazobactam 3.375 g IV every 6 hours if polymicrobial or necrotising concern

›Add vancomycin 15 to 20 mg/kg IV every 8 to 12 hours if MRSA risk

Fournier's gangrene treatment

›Immediate surgical debridement

›Surgical emergency: do not delay for imaging if diagnosis is clinical

›Wide debridement of necrotic tissue until viable margins

›Broad-spectrum IV antibiotics

›Piperacillin-tazobactam 3.375 g IV every 6 hours plus

›Vancomycin 15 to 20 mg/kg IV every 8 to 12 hours plus

›Metronidazole 500 mg IV every 8 hours for anaerobic coverage

›Adjust based on culture results

›Adjunctive hyperbaric oxygen

›Consider at centres with availability as adjunct to surgical debridement

Non-infectious and dermatological treatment

›Irritant or contact dermatitis

›Remove offending agent

›Hydrocortisone 1% cream topically twice daily for 5 to 7 days

›Emollients for barrier restoration

›Non-specific inflammatory or recurrent balanitis

›Pimecrolimus 1% cream topically twice daily

›Evidence from Georgala et al. 2007 supporting use in recurrent non-specific balanitis

›Hydrocortisone 1% cream short course as alternative

›Avoid potent topical steroids long-term on genital mucosa (risk of atrophy)

›Lichen sclerosus (balanitis xerotica obliterans)

›Clobetasol propionate 0.05% cream topically once daily for 4 to 12 weeks

›Potent topical corticosteroid is first-line

›Urology follow-up mandatory for premalignant monitoring

›Circumcision: curative for phimosis; does not eliminate malignancy risk

›Zoon (plasma cell) balanitis

›Tacrolimus 0.1% cream topically twice daily

›Effective in case series; reduces inflammation

›Circumcision is definitive treatment

›Topical mupirocin: case reports of resolution with monotherapy (Lee and Cohen, JDD 2017)

›Circinate balanitis (reactive arthritis-associated)

›Treat underlying reactive arthritis

›NSAIDs for joint and mucocutaneous inflammation

›Dapsone for severe or refractory circinate balanitis (Bakkour et al., CED 2014)

Procedural interventions

›Paraphimosis reduction

›Manual compression of oedema with bimanual pressure for 5 to 10 minutes

›Then reduce foreskin over glans with thumbs on distal glans and fingers proximal

›Local anaesthetic penile block prior to reduction in severe cases

›If manual reduction fails: emergency dorsal slit by urology

›Biopsy for atypical or refractory lesions

›Punch biopsy 3 to 4 mm under local anaesthesia

›Send for histopathology and consider PAS stain for fungi

›Circumcision

›Definitive treatment for recurrent balanitis in uncircumcised men

›Consider in phimosis, lichen sclerosus, Zoon balanitis

›Reduces recurrence rate significantly

Diabetes management in balanitis

›Glycaemic optimisation

›Screen all recurrent or refractory cases with fasting glucose and HbA1c

›Target HbA1c < 53 mmol/mol (7%) to reduce candidal recurrence

›Initiate or optimise hypoglycaemic therapy in collaboration with primary care

›SGLT2 inhibitors increase genital infection risk; counsel patients on this

09Special Populations/sp41

Pregnancy

›Balanitis considerations in pregnant partners

›Candidal balanitis in male partners of pregnant women

›Topical clotrimazole 1% safe and preferred for male partner treatment

›Oral fluconazole: avoid during pregnancy (teratogenicity concern in high doses)

›Concurrent vaginal candidiasis treatment essential to prevent reinfection

›Partner treatment approach

›Topical antifungal for male partner during partner's pregnancy

›Maternal candidal vaginitis treatment with clotrimazole vaginal pessary

›STI testing important as part of antenatal STI screen for partner

›No physiological changes of pregnancy apply directly to male patients

›Ensure partner antibiotic or antifungal safety reviewed by obstetric team

Geriatric

›Increased risk profile in older adults

›Age > 40 years: OR 2.27 for candidal balanitis

›Comorbid diabetes more prevalent; screen at every presentation

›Immobility and incontinence increase maceration and candidal risk

›Malignancy vigilance

›Chronic balanitis is an independent risk factor for penile SCC

›Any non-healing, atypical, or treatment-refractory lesion requires biopsy in older men

›Erythroplasia of Queyrat and Zoon balanitis most common in older uncircumcised men

›Medication considerations

›Polypharmacy increases fixed drug eruption risk

›Corticosteroid use increases candidal susceptibility

›Renal impairment: adjust fluconazole dose if eGFR < 50 ml/min/1.73m2

›Functional and hygiene barriers

›Arthritis or cognitive impairment may limit foreskin hygiene

›Carer education for hygiene in dependent older adults

10Background/b60

Epidemiology

›Prevalence and incidence

›Affects up to 11% of men attending STI clinics

›Overwhelmingly a disease of uncircumcised males

›Accounts for 3 to 11% of all male genitourinary consultations in community settings

›Risk factor distribution

›Uncircumcised status: virtually all cases occur in uncircumcised men

›Diabetes mellitus: 2.85x relative risk; the most important modifiable risk factor

›Age > 40 years: OR 2.27 for candidal balanitis (Lisboa et al., JEADV 2010)

›Immunosuppression: HIV, chemotherapy, chronic corticosteroids

›Obesity and metabolic syndrome: independent risk contributors

›Aetiology distribution

›Infectious: ~54% of cases

›Candida albicans most common infectious cause

›Non-infectious: ~41% of cases

›Irritant dermatitis, psoriasis, lichen sclerosus, Zoon balanitis

›Premalignant or malignant: <5% of cases

›Recurrence rate

›Approximately 13% recurrence even with appropriate treatment

›Recurrence triggers diabetes evaluation and circumcision discussion

Pathophysiology

›Anatomical predisposition in uncircumcised males

›Subpreputial space creates warm, moist anaerobic microenvironment

›Smegma accumulation promotes bacterial and fungal colonisation

›Phimosis impairs hygiene and increases risk of irritant and microbial exposure

›Infectious mechanisms

›Candida albicans

›Dimorphic fungus switching from commensal to pathogen

›Hyperglycaemia provides high glucose environment promoting pseudohyphae formation

›Disrupted local immunity in diabetes allows mucosal invasion

›Bacterial pathogens

›Staphylococcus and Streptococcus exploit skin barrier disruption

›Gardnerella vaginalis acquired from sexual partner with bacterial vaginosis

›Anaerobic overgrowth in smegma under phimotic foreskin

›Non-infectious inflammatory mechanisms

›Irritant dermatitis: direct toxic damage to genital epithelium from soaps or chemicals

›Psoriasis: Th17-mediated immune dysregulation; genital skin affected in 29 to 40% of psoriasis patients

›Lichen sclerosus: T-cell-mediated autoimmune destruction of subepithelial tissue

›Zoon balanitis: likely chronic irritant or infectious origin; dense plasma cell infiltrate on histology

›Malignant transformation pathway

›Chronic balanitis is an independent risk factor for penile SCC

›Erythroplasia of Queyrat represents HPV-associated or HPV-independent carcinoma in situ

›Untreated lichen sclerosus carries estimated 4 to 5% lifetime risk of penile SCC

Therapeutic Considerations

›Treatment selection rationale

›Clinical diagnosis drives initial therapy; microbiological confirmation for refractory cases

›Candidal balanitis: topical azoles are first-line; oral fluconazole for recurrence

›Bacterial balanitis: topical antibiotics sufficient for localised disease; oral or IV for cellulitis

›Non-infectious: remove irritant; low-potency steroid short course; immunomodulator for refractory

›Diabetes optimisation as core treatment

›HbA1c reduction is disease-modifying in recurrent candidal balanitis

›SGLT2 inhibitors increase genital mycotic infection risk by 3 to 5-fold; counsel appropriately

›Glycaemic targets: HbA1c < 53 mmol/mol (7%) associated with reduced genital infection frequency

›Circumcision as definitive intervention

›Eliminates subpreputial space; effectively prevents recurrent balanitis

›Effective for lichen sclerosus-associated phimosis

›Curative for Zoon balanitis

›Does not fully eliminate penile SCC risk from lichen sclerosus

›Evidence hierarchy for treatment choices

›Topical clotrimazole and miconazole: Class I recommendation for candidal balanitis

›Oral fluconazole for recurrent candida: supported by STI treatment guidelines (CDC/MMWR 2021)

›Pimecrolimus for non-specific recurrent balanitis: RCT evidence (Georgala et al. Dermatology 2007)

›Clobetasol for lichen sclerosus: consensus recommendation; no large RCT in penile disease

11Patient Discharge Instructions/pdi32

copy discharge instructions

›Diagnosis and overview

›Balanitis is inflammation of the tip of the penis (glans) and sometimes the foreskin

›It is common in uncircumcised men and is usually caused by a yeast or bacteria

›Most cases resolve within 1 to 2 weeks with appropriate treatment

›Hygiene instructions

›Gently retract the foreskin and rinse with warm water only — no soap on the glans

›Pat the area dry after washing; keep the skin dry between washes

›Avoid all scented soaps, lubricants, and condoms until fully healed

›Wear loose-fitting cotton underwear to reduce moisture and friction

›Medication instructions

›Apply all creams as prescribed to the tip of the penis and inner foreskin

›Complete the full course of treatment even if symptoms improve

›Do not use the cream on other skin areas; keep away from eyes

›If prescribed oral medication, take with or without food as tolerated

›Activity and sexual health

›Avoid sexual activity until symptoms fully resolve to prevent reinfection

›If a yeast infection is the cause, your sexual partner may need treatment too; discuss with your doctor

›Use a condom after recovery if STI was a contributing factor

›Diabetes management

›If you have diabetes, good blood sugar control is the most important step to prevent recurrence

›Follow up with your family doctor to review your diabetes medications if recurrence occurs

›Return to emergency department immediately if

›The foreskin becomes stuck behind the tip of the penis and cannot be pulled back (paraphimosis)

›Redness and swelling spread to the shaft, scrotum, or groin

›You develop fever, chills, or feel generally unwell

›You are unable to urinate

›There is a foul-smelling discharge, black skin, or you feel the skin crackling (Fournier's gangrene signs)

12References/r39

Guidelines and key sources

›Lisboa C, Ferreira A, Resende C, Rodrigues AG

›Infectious balanoposthitis: management, clinical and laboratory features

›International Journal of Dermatology 2009; PMID 19200183

›Mallon E, Hawkins D, Dinneen M, et al

›Circumcision and genital dermatoses

›Archives of Dermatology 2000; JAMA Network

›Workowski KA, Bachmann LH, Chan PA, et al

›Sexually transmitted infections treatment guidelines, 2021

›MMWR Recommendations and Reports 2021; PMC8344968

›Georgala S, Gregoriou S, Georgala C, et al

›Pimecrolimus 1% cream in non-specific inflammatory recurrent balanitis

›Dermatology 2007; PMID 17823517

›Lisboa C, Santos A, Dias C, et al

›Candida balanitis: risk factors

›JEADV 2010; PMID 20002652

›Errichetti E, Lallas A, Di Stefani A, et al

›Accuracy of dermoscopy in distinguishing erythroplasia of Queyrat from balanitis

›JEADV 2019; PMID 30468529

›Taudorf EH, Jemec GBE, Hay RJ, Saunte DML

›Cutaneous candidiasis: evidence-based review of topical and systemic treatments

›JEADV 2019; PMID 31287594

›Tu CJ, Torrez S, Chen BG, Brown LA, Randall MM

›Balanoposthitis in children: does treatment matter?

›Journal of Emergency Medicine 2025; PMID 41252897

›Brouwer OR, Albersen M, Parnham A, et al

›EAU-ASCO collaborative guideline on penile cancer: 2023 update

›European Urology 2023

Learn More: Balanitis→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.